Opinion|Videos|March 29, 2025
Future Directions for GPP Management and Key Takeaways
Panelists discuss spesolimab’s place in therapy for treating generalized pustular psoriasis (GPP), address remaining unmet treatment needs, and share the types of future data they would like to see, along with key takeaways and advice for dermatologists managing patients with GPP.
Advertisement
Video content above is prompted by the following:
Episodes in this series
- In your opinion, what is spesolimab’s place in therapy when treating GPP?
a. What unmet treatment needs remain, and what data would you like to see in the future? - What are some key takeaways or advice for other dermatologists who are managing patients with GPP?
Advertisement
Related to this article
Catch up on HCPLive’s second-half Fall Clinical 2026 coverage, from HS underdiagnosis in men and long-term acne data to advanced cutaneous SCC care.
In mice, liraglutide reduced steatosis through PPARα without needing iNKT cells, pointing to a possible GLP-1 RA plus PPARα combination.
In pooled, propensity-matched data, SC infliximab achieved week 54 endoscopic response in 65.7% of patients with ileal Crohn’s disease vs 27.1% with IV.
In ADtouch, lebrikizumab improved clearance, itch, and pain in hand and foot atopic dermatitis. Shawn Kwatra, MD, discusses what the data mean.
Phase 3 SHINE-2 data show 41.3% of children and adolescents with UC reached clinical remission after 12 weeks of mirikizumab induction.
A roundup of highlights from EADV Congress 2026 in Vienna, spanning dupilumab real-world data, pipeline biologics, and a first-in-class oral agent.
Among 155 patients aged 0 to 24 months, 96.1% of episodes were food-triggered and 90.4% of epinephrine recipients received only 1 dose.
In a LIBERTY post hoc analysis, most patients restarting infliximab as SC 240 mg after a drug holiday had prior ADAs, yet outcomes were similar.
Advertisement
Advertisement
Trending on HCPLive
1
Oral Icotrokinra Sustains UC Response Through 76 Weeks in ANTHEM-UC LTE
2
Guselkumab Sustains Histologic Healing in Ulcerative Colitis Over 3 Years
3
Rezpegaldesleukin Hair Regrowth Climbs Through 1 Year in AA: David Rosmarin, MD
4
EADV Congress 2026: 5 Atopic Dermatitis Headlines to Know
5